Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 7, 2024

Primary Completion Date

August 5, 2024

Study Completion Date

September 4, 2024

Conditions

Safety and TolerabilityHealthy Volunteers

Interventions

DRUG

AK1967 (Procizumab)

DPP3 inhibition using the humanized monoclonal antibody AK1967 (Procizumab)

DRUG

Placebo

Application of placebo

Trial Locations (1)

Radboud University Medical Center, Nijmegen